

Dissolution Testing in Quality Control and Drug Development - from USP Vessels to Artificial Intelligence

October 20, 2020, Gothenburg, Sweden

Preliminary program

October 20

- 09.00 Registration with coffee/tea and sandwich
- 09.20 **Introduction**
- 09.30 **Quality Control perspective – dissolution and disintegration methods and validation**
James Mann, AstraZeneca
- 10.05 **Regulatory landscape of dissolution**
Anders Lindahl, MPA
- 10.40 *Coffee/tea and exhibition*
- 11.15 **Equipment used for dissolution**
Jonas Johansson, AstraZeneca
- 11.50 *Lunch*
- 12.50 **Bio relevant media**
Jennifer Dressmann, Goethe University
- 13.25 **Dissolution – for in-vivo predictions**
Christer Tannergren
- 14.00 **Efficacy – immediate (IR) and modified release (MR)**
Susanna Abrahamsén Alami, AstraZeneca
- 14.35 *Coffee/tea with refreshments and exhibition*
- 14.50 **Dissolution testing – alternative administration routes e.g. inhalation and parenteral**
Nikoletta Fotaki, University of Bath, UK

- 15.25 **Increase bioavailability**
Christel Bergström
- 16.00 **Dissolution - test of generics to secure quality to patient**
Johan Breitholz, AstraZeneca
- 16.35 Wrap -up